Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

25

Revenue 2017

CSL

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of CSL's 2013 sales performance.

Shire’s angioedema drug Takhzyro claims EU approval

Shire’s angioedema drug Takhzyro claims EU approval

The switchovers includes some patients on Cinryze but also competitors’ products, he said.  At the moment Shire’s big competitor in HAE is CSL with its Haegarda product, a subcutaneous medicine

Shire’s angioedema drug Takhzyro recommended in Europe

Shire’s angioedema drug Takhzyro recommended in Europe The drug isn’t the first HAE treatment on the market, however: CSL’s subcutaneous therapy Haegarda gained approval in 2017 - despite Shire's legal efforts to block it with claims ... CSL’s drug has showed a median reduction in monthly attacks of

Roche gets wider approval for haemophilia drug Hemlibra

Roche gets wider approval for haemophilia drug Hemlibra Adynovate, Biogen’s Eloctate, Bayer’s Kovaltry and CSL Behring’s Afstyla – with the advantage of being dosed every one, two, or four weeks depending on need, rather than multiple times

Bayer roll-out of haemophilia drug Jivi gathers pace

Bayer roll-out of haemophilia drug Jivi gathers pace and Eloctate, and CSL Behring’s Afstyla, uptake hasn’t been as quick as many had hoped, so Jivi is entering a challenging market.

Roche highlights Hemlibra data as key FDA date approaches

Roche highlights Hemlibra data as key FDA date approaches every few days, such as Shire’s Adynovate, Biogen’s Eloctate, Bayer’s Kovaltry and CSL Behring’s Afstyla, uptake hasn’t been as quick as hoped.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics